Auxilium licenses Vivus's erectile dysfunction drug Stendra
This article was originally published in Scrip
Now that Auxilium Pharmaceuticals has licensed Stendra (avanafil) for up to $300m plus royalties and plans to launch the erectile dysfunction drug toward the end of 2013 – more than a year and a half after the product's US FDA approval – the new management team at Vivus can cross one major item off of its to-do list.
You may also be interested in...
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.